Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-03-09

FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate) submitted by Gilead Sciences …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COMPLERA (Emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)

Snippet

SUPPL AP for COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE)